122 related articles for article (PubMed ID: 27146585)
1. Plasma S100P level as a novel prognostic marker of metastatic breast cancer.
Peng C; Chen H; Wallwiener M; Modugno C; Cuk K; Madhavan D; Trumpp A; Heil J; Marmé F; Nees J; Riethdorf S; Schott S; Sohn C; Pantel K; Schneeweiss A; Yang R; Burwinkel B
Breast Cancer Res Treat; 2016 Jun; 157(2):329-338. PubMed ID: 27146585
[TBL] [Abstract][Full Text] [Related]
2. Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer.
Peng C; Wallwiener M; Rudolph A; Ćuk K; Eilber U; Celik M; Modugno C; Trumpp A; Heil J; Marmé F; Madhavan D; Nees J; Riethdorf S; Schott S; Sohn C; Pantel K; Schneeweiss A; Chang-Claude J; Yang R; Burwinkel B
Int J Cancer; 2016 May; 138(10):2499-509. PubMed ID: 26686298
[TBL] [Abstract][Full Text] [Related]
3. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients.
Wang G; Platt-Higgins A; Carroll J; de Silva Rudland S; Winstanley J; Barraclough R; Rudland PS
Cancer Res; 2006 Jan; 66(2):1199-207. PubMed ID: 16424059
[TBL] [Abstract][Full Text] [Related]
4. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients.
Maciejczyk A; Łacko A; Ekiert M; Jagoda E; Wysocka T; Matkowski R; Hałoń A; Györffy B; Lage H; Surowiak P
Histol Histopathol; 2013 Apr; 28(4):513-24. PubMed ID: 23364898
[TBL] [Abstract][Full Text] [Related]
5. A novel truncated form of S100P predicts disease-free survival in patients with lymph node positive breast cancer.
Chung L; Phillips L; Lin MZ; Moore K; Marsh DJ; Boyle FM; Baxter RC
Cancer Lett; 2015 Nov; 368(1):64-70. PubMed ID: 26276712
[TBL] [Abstract][Full Text] [Related]
6. S100P, a potential novel prognostic marker in colorectal cancer.
Wang Q; Zhang YN; Lin GL; Qiu HZ; Wu B; Wu HY; Zhao Y; Chen YJ; Lu CM
Oncol Rep; 2012 Jul; 28(1):303-10. PubMed ID: 22552710
[TBL] [Abstract][Full Text] [Related]
7. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
Darlix A; Hirtz C; Thezenas S; Maceski A; Gabelle A; Lopez-Crapez E; De Forges H; Firmin N; Guiu S; Jacot W; Lehmann S
BMC Cancer; 2019 Jan; 19(1):110. PubMed ID: 30700265
[TBL] [Abstract][Full Text] [Related]
9. Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
Wu Z; Boonmars T; Nagano I; Boonjaraspinyo S; Srinontong P; Ratasuwan P; Narong K; Nielsen PS; Maekawa Y
Int J Cancer; 2016 Jan; 138(2):396-408. PubMed ID: 26312563
[TBL] [Abstract][Full Text] [Related]
10. Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary.
Umezaki Y; Ito M; Nakashima M; Mihara Y; Kurohama H; Yatsunami N; Yasuhi I
Int J Gynecol Cancer; 2015 Nov; 25(9):1582-6. PubMed ID: 26397155
[TBL] [Abstract][Full Text] [Related]
11. Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy.
Mei Y; Liu H; Sun X; Li X; Zhao S; Ma R
Tumour Biol; 2017 Jun; 39(6):1010428317700002. PubMed ID: 28621233
[TBL] [Abstract][Full Text] [Related]
12. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the predictive efficiency of S100P on adverse prognosis and the pathogenesis of S100P-mediated invasion and metastasis of colon adenocarcinoma.
Shen ZY; Fang Y; Zhen L; Zhu XJ; Chen H; Liu H; Jiang B; Li GX; Deng HJ
Cancer Genet; 2016 Apr; 209(4):143-53. PubMed ID: 26975699
[TBL] [Abstract][Full Text] [Related]
14. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
Rochefort P; Chabaud S; Pierga JY; Tredan O; Brain E; Bidard FC; Schiffler C; Polena H; Khalil-Mgharbel A; Vilgrain I; Bachelot T
Br J Cancer; 2017 Jan; 116(3):356-361. PubMed ID: 28056463
[TBL] [Abstract][Full Text] [Related]
15. Identification of high independent prognostic value of nanotechnology based circulating tumor cell enumeration in first-line chemotherapy for metastatic breast cancer patients.
Liu XR; Shao B; Peng JX; Li HP; Yang YL; Kong WY; Song GH; Jiang HF; Liang X; Yan Y
Breast; 2017 Apr; 32():119-125. PubMed ID: 28157583
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
17. S100P predicts prognosis and drug resistance in gastric cancer.
Ge F; Wang C; Wang W; Wu B
Int J Biol Markers; 2013 Dec; 28(4):e387-92. PubMed ID: 23722300
[TBL] [Abstract][Full Text] [Related]
18. The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies.
Yang R; Stöcker S; Schott S; Heil J; Marme F; Cuk K; Chen B; Golatta M; Zhou Y; Sutter C; Wappenschmidt B; Schmutzler R; Bugert P; Qu B; Bartram CR; Sohn C; Schneeweiss A; Burwinkel B
Carcinogenesis; 2017 Mar; 38(3):312-320. PubMed ID: 28426874
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M
Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of circulating tumor cells in metastatic breast cancer.
Lang JE; Scott JH; Wolf DM; Novak P; Punj V; Magbanua MJ; Zhu W; Mineyev N; Haqq CM; Crothers JR; Esserman LJ; Tripathy D; van 't Veer L; Park JW
Breast Cancer Res Treat; 2015 Jan; 149(1):121-31. PubMed ID: 25432738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
